Download - Highlights from ACR: guselkumab, ixekizumab and secukinumab in SpA

Discover

Podcast Features
Your all-in-one podcasting solution.

Blog to Podcast
Turn your blog into an engaging podcast.
Livestream
High-performing audio live, without limits.

Podcast Studio
Easy-to-use audio recorder app.
Podbean AI
AI-Enhanced Audio Quality and Content Generation.

Podcast App
The best podcast player & podcast app.

Ads Marketplace
Join Ads Marketplace to earn money
through sponsorship on your podcast.

PodAds
Manage your ads with dynamic ad insertion capability.
Apple Podcasts Subscriptions Integration
Effortlessly publish and manage exclusive episodes for your
Apple Podcasts subscribers directly from Podbean.
Live Streaming
Receive livestream rewards from your audience and earn
recurring income from your Fan Club membership.

All Arts Business Comedy Education
Fiction Government Health & Fitness History Kids & Family
Leisure Music News Religion & Spirituality Science
Society & Culture Sports Technology True Crime TV & Film
Live

How to Start a Podcast
How to Start a Live Podcast
How to Monetize a podcast
How to Promote Your Podcast
How to Use Group Recording

Log in
Start your podcast for free

Podcasting
Monetization
Advertisers
Enterprise
Pricing
Discover

ARD Podcast

Health & Fitness:Medicine

Highlights from ACR: guselkumab, ixekizumab and secukinumab in SpA

2020-01-23

Download

Atul Deodhar, from the Oregon Health & Science University, provides an overview of recent clinical trial results in the area of seronegative Spondylarthritis. He presented the 24-week data of Guselkumab in active psoriatic arthritis patients in the DISCOVER-1 study and compared the phase 3 trials in non-radiographic SpA patients on Ixekizumab (COAST-X) and Secukinumab (PREVENT) with up to 52 week data available.